ZA202311798B - Stable liquid pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto - Google Patents

Stable liquid pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto

Info

Publication number
ZA202311798B
ZA202311798B ZA2023/11798A ZA202311798A ZA202311798B ZA 202311798 B ZA202311798 B ZA 202311798B ZA 2023/11798 A ZA2023/11798 A ZA 2023/11798A ZA 202311798 A ZA202311798 A ZA 202311798A ZA 202311798 B ZA202311798 B ZA 202311798B
Authority
ZA
South Africa
Prior art keywords
medium chain
chain triglycerides
high drug
pharmaceutical compositions
liquid pharmaceutical
Prior art date
Application number
ZA2023/11798A
Other languages
English (en)
Inventor
Julie Liu Aikun
KAASGAARD Thomas
NAIR C K BALACHANDRAN Murali
T Henderson Samuel
BOYD Benjamin
Original Assignee
Cerecin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerecin Inc filed Critical Cerecin Inc
Publication of ZA202311798B publication Critical patent/ZA202311798B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2023/11798A 2021-05-25 2023-12-21 Stable liquid pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto ZA202311798B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192826P 2021-05-25 2021-05-25
PCT/US2022/030819 WO2022251288A1 (en) 2021-05-25 2022-05-25 Stable liquid pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto

Publications (1)

Publication Number Publication Date
ZA202311798B true ZA202311798B (en) 2025-04-30

Family

ID=82115983

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/11798A ZA202311798B (en) 2021-05-25 2023-12-21 Stable liquid pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto

Country Status (10)

Country Link
US (1) US20240238199A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346758A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519999A (cg-RX-API-DMAC7.html)
KR (1) KR20240012539A (cg-RX-API-DMAC7.html)
CN (1) CN117460495A (cg-RX-API-DMAC7.html)
AU (1) AU2022283278A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220907A1 (cg-RX-API-DMAC7.html)
IL (1) IL308512A (cg-RX-API-DMAC7.html)
WO (1) WO2022251288A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202311798B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024384650A1 (en) * 2023-11-26 2026-07-09 Cerecin Australia Pty Limited Formulations of lipid nano emulsions with controlled pharmacokinetic profiles and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08505367A (ja) * 1992-10-16 1996-06-11 スミスクライン・ビーチャム・コーポレイション 医薬用エマルジョン組成物
ES2553132T3 (es) * 2008-04-22 2015-12-04 Azelis Deutschland Kosmetik Gmbh Utilización de ésteres de ácido cítrico como emulsionantes W/O
BR112016018673B1 (pt) * 2014-02-14 2023-10-17 Jingjun Huang Composição em nanoemulsão de óleo em água estável opticamente clara, método de produção da mesma, e, formulação de carreador
EA201992178A1 (ru) * 2017-03-15 2020-05-22 Сересин Инк. Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними
EP3934630A4 (en) * 2019-03-04 2022-11-23 Cerecin Inc. MEDIUM CHAIN TRIGLYCERIDE FORMULATIONS WITH IMPROVED BIOAVAILABILITY AND RELATED METHODS
US11857931B2 (en) * 2020-01-07 2024-01-02 WAKAMONO joint stock company Process for production of nano-microemulsion system of plant oil triglycerides

Also Published As

Publication number Publication date
AU2022283278A1 (en) 2024-01-18
JP2024519999A (ja) 2024-05-21
WO2022251288A1 (en) 2022-12-01
EP4346758A1 (en) 2024-04-10
KR20240012539A (ko) 2024-01-29
US20240238199A1 (en) 2024-07-18
IL308512A (en) 2024-01-01
CN117460495A (zh) 2024-01-26
CA3220907A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
PH12019502096A1 (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
Lohr et al. Oxidative mechanisms and tardive dyskinesia
Liu et al. Heme oxygenase‐1: The roles of both good and evil in neurodegenerative diseases
Nakanishi et al. Microglia-aging: roles of microglial lysosome-and mitochondria-derived reactive oxygen species in brain aging
Richard et al. Necroptosis in Alzheimer’s disease: Potential therapeutic target
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
Yu et al. The role of reactive oxygen species in Alzheimer's disease: from mechanism to biomaterials therapy
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
Bitra et al. Effect of wheat grass powder on aluminum induced Alzheimer's disease in Wistar rats
Beytut et al. The possible protective effects of vitamin E and selenium administration in oxidative stress caused by high doses of glucocorticoid administration in the brain of rats
MX2021015874A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
Cai et al. Oxidative stress and acute pancreatitis
Pattanaik et al. Toxicology and free radicals scavenging property of Tamra bhasma
Menéndez et al. Nanopharmacology as a new approach to treat neuroinflammatory disorders
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
Ghasemi et al. Neuroprotective actions of norepinephrine in neurological diseases
ZA202304463B (en) Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
Ding et al. Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease
PH12020551470A1 (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
Zhang et al. Involvement of histone methylation in the regulation of neuronal death: Zhang et al.
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
WO2023039345A3 (en) Treatment of neurological disorders
Eckert et al. Improvement of age-related neurocognitive disorders by Ginkgo biloba extract: neuroprotection in focus
MX2024010401A (es) Quiméricos dirigido a proteólisis (protac) de proteína de translocación del linfoma del tejido linfoide asociado a las mucosas 1 (malt1)